To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM

PHASE3CompletedINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

March 21, 2024

Study Completion Date

March 21, 2024

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

JW0201

JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)

DRUG

Placebo

C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)

Trial Locations (1)

Chosun University Hospital, Gwangju